Copyright
©The Author(s) 2019.
World J Gastroenterol. Feb 21, 2019; 25(7): 789-807
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Table 2 Randomized phase II, phase III clinical trials of early / intermediate stage hepatocellular carcinoma
Target population | Design | Trial name | Result | Presentation | Publication | 1st author | |
Early | Adjuvant (prevention of recurrence) | 1 Vitamin K2 vs Placebo | Negative | Hepatology 2011[21] | Yoshida H | ||
2 Peretinoin vs Placebo | NIK-333 | Negative | ASCO 2010 | JG 2014[22] | Okita K | ||
3 Sorafenib vs Placebo | STORM | Negative | ASCO 2014 | Lancet-O 2015[23] | Bruix J | ||
4 Peretinoin vs Placebo | NIK-333/K-333 | Ongoing | |||||
Improvement of RFA | 1 RFA +/- LTLD | HEAT | Negative | ILCA 2013 | CCR 2017[24] | Tak WY | |
2 RFA +/- LTLD | OPTIMA | ||||||
Intermediate | Improvement of TACE | 1 TACE +/- Sorafenib | Post-TACE | Negative | ASCO-GI 2010 | EJC 2011[25] | Kudo M |
2 TACE +/- Sorafenib | SPACE (Ph II) | Negative | ASCO-GI 2012 | J Hepatol 2016[26] | Lencioni R | ||
3 TACE +/- Brivanib | BRISK-TA | Negative | ILCA 2013 | Hepatol 2014[27] | Kudo M | ||
4 TACE +/- Orantinib | ORIENTAL | Negative | EASL 2015 | Lancet GH 2017[28] | Kudo M | ||
5 TACE +/- Sorafenib | TACE-2 | Negative | ASCO 2016 | Lancet GH 2017[29] | Meyer T | ||
6 TACE +/- Sorafenib | TACTICS (Ph II) | Positive | ASCO-GI 2018[30] | Kudo M |
- Citation: Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807
- URL: https://www.wjgnet.com/1007-9327/full/v25/i7/789.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i7.789